| Autor: |
Jens Thomsen, Najiba M. Abdulrazzaq, Peter S. Nyasulu, Farida Al Hosani, Maya Habous, Stefan Weber, Fouzia Jabeen, The UAE AMR Surveillance Consortium, Godfred Antony Menezes, Carole Ayoub Moubareck, Abiola Senok, Dean B. Everett, Adnan Alatoom, Agnes Sonnevend-Pal, Ahmed Abdulkareem Al Hammadi, Ahmed Elhag Ahmed, Ahmed F. Yousef, Alaa MM Enshasy, Amal Mubarak Madhi, Amna AlBlooshi, Andreas Podbielski, Anju Nabi, Anup Shashikant Poddar, Arun Kumar Jha, Ayesha Abdulla Al Marzooqi, Bashir Aden, Dean Everett, Deeba Jafri, Duckjin Hong, Emmanuel Fru Nsutebu, Farah Ibrahim Al-Marzooq, Fatima Al Dhaheri, Francis Amirtharaj Selvaraj, Ghada Abdel Wahab, Ghalia Abdul Khader Khoder, Gitanjali Avishkar Patil, Godfred A. Menezes, Muhammad Ghulam Hadayatullah, Hafiz Ahmad, Hala Ahmed Fouad Ismail, Hazim Khalifa, Husein Alzabi, Ibrahim Alsayed Mustafa Alhashami, Imene Lazreg, Irfaan Akthar, John Stelling, Kaltham Ali Kayaf, Kavita Diddi, Krishnaprasad Ramabhadran, Laila Al Dabal, Laura Thomsen, Chamani-Tabriz Leili, Madikay Senghore, Manal Abdel Fattah Ahmed, Moeena Zain, M. Sheek-Hussein Mohamud, Monika Maheshwari, Mubarak Saif Alfaresi, Mushtaq Khan, Najiba Abdulrazzaq, Nehad Nabeel Al Shirawi, Nesrin Helmy, Pamela Fares Murad, Pascal Frey, Peter Nyasulu, Prashant Nasa, T. A. Patil Rajeshwari, Rania El Lababidi, Ratna A. Kurahatti, Riyaz Amirali Husain, Robert Lodu Serafino Wani Swaka, Saeed Hussein, Sameh Soliman, Savitha Mudalagiriyappa, Seema Oommen, Shaikha Ghannam Alkaabi, Simantini Jog, Siobhan O‘Sullivan,, Somansu Basu, Sura Khamees Majeed, Syed Irfan Hussein Rizvi, Tibor Pal, Timothy Anthony Collyns, Yassir Mohammed Eltahir Ali, Yousuf Mustafa Naqvi, Zahir Osman Babiker, Omar Al Deesi Zulfa |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Frontiers in Public Health, Vol 12 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2296-2565 |
| DOI: |
10.3389/fpubh.2024.1244353 |
| Popis: |
IntroductionThe Eastern Mediterranean Regional Office (EMRO) region accounts for almost 8% of all global Mycobacterium tuberculosis (TB) cases, with TB incidence rates ranging from 1 per 100,000 per year in the United Arab Emirates (UAE) to 204 per 100,000 in Djibouti. The national surveillance data from the Middle East and North Africa (MENA) region on the epidemiology and antimicrobial resistance trends of TB, including MDR-TB remains scarce.MethodsA retrospective 12-year analysis of N = 8,086 non-duplicate diagnostic Mycobacterium tuberculosis complex (MTB complex) isolates from the UAE was conducted. Data were generated through routine patient care during the 2010–2021 years, collected by trained personnel and reported by participating surveillance sites to the UAE National Antimicrobial Resistance (AMR) Surveillance program. Data analysis was conducted with WHONET, a windows-based microbiology laboratory database management software developed by the World Health Organization Collaborating Center for Surveillance of Antimicrobial Resistance, Boston, United States (https://whonet.org/).ResultsA total of 8,086 MTB-complex isolates were analyzed. MTB-complex was primarily isolated from respiratory samples (sputum 80.1%, broncho-alveolar lavage 4.6%, pleural fluid 4.1%). Inpatients accounted for 63.2%, including 1.3% from ICU. Nationality was known for 84.3% of patients, including 3.8% Emiratis. Of UAE non-nationals, 80.5% were from 110 countries, most of which were Asian countries. India accounted for 20.8%, Pakistan 13.6%, Philippines 12.7%, and Bangladesh 7.8%. Rifampicin-resistant MTB-complex isolates (RR-TB) were found in 2.8% of the isolates, resistance to isoniazid, streptomycin, pyrazinamide, and ethambutol, was 8.9, 6.9, 3.4 and 0.4%, respectively. A slightly increasing trend of resistance among MTB-complex was observed for rifampicin from 2.5% (2010) to 2.8% (2021).ConclusionInfections due to MTB-complex are relatively uncommon in the United Arab Emirates compared to other countries in the MENA region. Most TB patients in the UAE are of Asian origin, mainly from countries with a high prevalence of TB. Resistance to first line anti-tuberculous drugs is generally low, however increasing trends for MDR-TB mainly rifampicin linked resistance is a major concern. MDR-TB was not associated with a higher mortality, admission to ICU, or increased length of hospitalization as compared to non-MDR-TB. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
